This segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Hengrui Medicine is actively involved in discovering and developing novel antineoplastic agents, including small molecule drugs, monoclonal antibodies, and antibody-drug conjugates. The company utilizes advanced technologies such as targeted drug delivery systems and precision medicine approaches to improve treatment outcomes and reduce side effects. This segment addresses significant unmet needs in oncology, aiming to provide more effective and personalized treatment options for patients. The company has a strong market position in China and is expanding globally through strategic partnerships and collaborations.

This segment concentrates on developing and marketing drugs for metabolic disorders, including diabetes, and cardiovascular diseases. Hengrui Medicine invests in research to discover new drug targets and develop innovative therapies to address these prevalent conditions. The company employs advanced drug discovery techniques, including high-throughput screening and structure-based drug design, to identify promising drug candidates. The focus is on improving patient outcomes by providing effective treatments that manage symptoms, prevent complications, and improve the overall quality of life. The company is strategically positioned to capitalize on the growing demand for treatments in these therapeutic areas, particularly in China and other emerging markets.

This segment is dedicated to the research, development, and commercialization of drugs for pain management and anesthesia. Hengrui Medicine is actively involved in discovering and developing novel analgesics and anesthetic agents to address various types of pain, including chronic pain, neuropathic pain, and post-operative pain. The company utilizes advanced technologies such as targeted drug delivery systems and precision medicine approaches to improve treatment outcomes and reduce side effects. This segment addresses significant unmet needs in pain management, aiming to provide more effective and personalized treatment options for patients. The company has a strong market position in China and is expanding globally through strategic partnerships and collaborations.

This segment encompasses the research, development, and commercialization of drugs for autoimmune diseases and other therapeutic areas. Hengrui Medicine is actively involved in discovering and developing novel therapies to address various autoimmune conditions, including rheumatoid arthritis and other inflammatory diseases. The company utilizes advanced technologies such as targeted drug delivery systems and precision medicine approaches to improve treatment outcomes and reduce side effects. This segment addresses significant unmet needs in autoimmune diseases, aiming to provide more effective and personalized treatment options for patients. The company has a strong market position in China and is expanding globally through strategic partnerships and collaborations.